The obesity medicine community has been watching Eli Lilly and Company (NYSE: LLY) closely, and the TRIUMPH-4 Phase 3 trial results have delivered on years of anticipation. As reported by CNBC and covered by financial and health media — including Yahoo Finance — Eli Lilly's retatrutide demonstrated what may be the most significant weight loss outcome ever recorded in a Phase 3 obesity trial.
At the 12mg dose, participants in TRIUMPH-4 achieved a mean body weight reduction of 28.7% over 68 weeks. To put that in clinical context: a person starting at 250 pounds would, on average, lose more than 70 pounds. That figure has no precedent in the history of large-scale, randomized, placebo-controlled obesity pharmacotherapy trials.
Retatrutide — commonly referred to as reta in patient communities — is a once-weekly subcutaneous injection that works as a triple agonist, simultaneously activating three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple-receptor mechanism distinguishes it from currently approved medications and is the scientific basis for its outsized efficacy signals. Some patient community members call it triple G as an informal shorthand, though the precise pharmacological term remains triple agonist.
The TRIUMPH-4 titration schedule used in the Phase 3 trial was deliberately gradual, beginning at 2mg (weeks 1–4), stepping up to 4mg (weeks 5–8), then 6mg (weeks 9–12), then 9mg (weeks 13–16), and finally reaching the 12mg maintenance dose at week 17 onward. This slow escalation is designed to minimize gastrointestinal side effects — the same dose-dependent nausea, diarrhea, and vomiting seen in the Phase 2 trial — by allowing the body time to adjust at each step.
Side effects observed in TRIUMPH-4 warrant honest discussion. Discontinuation rates were notably higher in the active arms: 18.2% in the 12mg group and 12.2% in the 9mg group, compared to 4.0% in the placebo group. Dysesthesia — an abnormal, often tingling or uncomfortable skin sensation — was reported in 20.9% of participants at the 12mg dose and 8.8% at 9mg, versus just 0.7% in the placebo group. This adverse event was also detected in the Phase 2 data, where it appeared in 12.9% of 12mg participants versus 1.4% on placebo. These figures reinforce the importance of individualized dosing and careful clinical monitoring as retatrutide moves toward potential regulatory review.
Notably, the Phase 3 peer-reviewed publication is still pending as of April 2026, and Eli Lilly has not yet filed a New Drug Application (NDA) with the FDA. The 28.7% figure comes from a press release issued December 11, 2025, and full peer-reviewed data will provide additional granularity on subgroup outcomes, safety, and cardiometabolic endpoints.
To understand just how significant a 28.7% mean weight loss at 68 weeks truly is, it helps to place that number alongside the current standard of care. The two most widely used injectable obesity medications — semaglutide and tirzepatide — have both demonstrated landmark efficacy in their own Phase 3 programs. Retatrutide's Phase 3 result now stands above both.
| Medication | Mechanism | Trial | Duration | Mean Weight Loss | FDA Status |
|---|---|---|---|---|---|
| Semaglutide 2.4mg (Wegovy) | GLP-1 agonist | STEP-1 | 68 weeks | ~14.9% | Approved |
| Tirzepatide 15mg (Zepbound) | GLP-1 / GIP dual agonist | SURMOUNT-1 | 72 weeks | ~20.9% | Approved |
| Retatrutide 12mg | GLP-1 / GIP / Glucagon triple agonist | TRIUMPH-4 | 68 weeks | 28.7% | Not yet approved; NDA not filed |
The mechanistic explanation for retatrutide's superior efficacy likely lies in the addition of glucagon receptor agonism. While GLP-1 reduces appetite and slows gastric emptying, and GIP amplifies the insulin response and may enhance fat metabolism, glucagon receptor activation increases energy expenditure — the body burns more calories even at rest. This combination addresses what many patients describe as food noise (the persistent mental preoccupation with eating and hunger) while also increasing the body's caloric output, creating a more powerful dual-sided energy balance effect than dual agonists alone.
The Phase 2 trial data, published in the New England Journal of Medicine in 2023 by Jastreboff et al., already hinted at this ceiling-breaking potential. At 48 weeks, 70% of participants in the 8mg group and 64% in the 12mg group lost at least 20% of their body weight. Up to 48% of 12mg participants lost 25% or more. The Phase 3 results have now confirmed and extended those signals at scale.
Strong efficacy data in Phase 3 is a necessary — but not sufficient — condition for FDA approval. Eli Lilly has not yet filed an NDA for retatrutide as of April 2026, and the full peer-reviewed Phase 3 dataset has not yet been published. The FDA's review process for a new molecular entity typically takes 10–12 months following NDA submission under standard review, or 6 months under Priority Review if granted.
The safety profile will receive rigorous scrutiny. The dysesthesia signal — present in both Phase 2 and TRIUMPH-4 — will need to be characterized thoroughly in terms of onset, severity, reversibility, and management. The higher discontinuation rates at 12mg relative to placebo will also factor into the benefit-risk assessment. These are not necessarily disqualifying findings, but they will shape labeling decisions, risk mitigation strategies, and post-marketing commitments if approval is granted.
On the efficacy side, the regulatory bar for obesity medications has evolved considerably. A mean weight loss of 28.7% — with presumably robust responder analyses showing substantial proportions of patients achieving 20%, 25%, and even 30% reductions — positions retatrutide as a compelling candidate. Cardiometabolic endpoints observed in Phase 2, including triglyceride reductions of up to 39% and LDL reductions approaching 17% at the higher doses, may support broader clinical claims if replicated in Phase 3.
Quality of life data from Phase 2 (SF-36v2 scores improved across all active dose groups at week 48) adds to the picture of a medication that may benefit patients not just on the scale, but in daily function, mobility, and wellbeing.
The timeline to potential FDA approval remains uncertain. Lilly has not publicly confirmed a submission date, and the peer-reviewed Phase 3 publication will be an important milestone before regulatory action is expected. Patients and clinicians should treat any specific approval timeline estimates with appropriate caution.
If you are following retatrutide's development and want to stay informed as new data emerges, glp3md.com maintains a waitlist for individuals who want to be among the first to receive updates on retatrutide's regulatory progress and clinical availability. Joining the waitlist carries no obligation and makes no promises about medication access, treatment, or prescriptions — retatrutide is not FDA-approved, and no guarantees can be made about future availability. It is simply a way to stay connected to accurate, clinically grounded information as this field continues to evolve rapidly. Join the glp3md waitlist here.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.